207 related articles for article (PubMed ID: 17433231)
1. [Basis for vaccine recommendations].
Lévy-Bruhl D
Med Sci (Paris); 2007 Apr; 23(4):404-8. PubMed ID: 17433231
[TBL] [Abstract][Full Text] [Related]
2. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
Patel MM; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
[TBL] [Abstract][Full Text] [Related]
3. [Contribution of mathematical modeling to vaccination decision making. Examples from varicella, rotavirus and papillomavirus vaccinations].
Lévy-Bruhl D
Bull Acad Natl Med; 2010 Nov; 194(8):1545-56; discussion 1557-8. PubMed ID: 22046716
[TBL] [Abstract][Full Text] [Related]
4. [The contribution of social medicine to vaccination in Austria].
Kunze M
Wien Med Wochenschr; 1998; 148(8-9):191-7. PubMed ID: 9677675
[TBL] [Abstract][Full Text] [Related]
5. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs.
Kimman TG; Boot HJ; Berbers GA; Vermeer-de Bondt PE; Ardine de Wit G; de Melker HE
Vaccine; 2006 May; 24(22):4769-78. PubMed ID: 16616803
[TBL] [Abstract][Full Text] [Related]
6. Evolving public perceptions and stability in vaccine uptake.
Reluga TC; Bauch CT; Galvani AP
Math Biosci; 2006 Dec; 204(2):185-98. PubMed ID: 17056073
[TBL] [Abstract][Full Text] [Related]
7. [Where do we stand with BCG vaccination programme in Japan?].
Mori T
Kekkaku; 2001 Apr; 76(4):385-97. PubMed ID: 11398330
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
10. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
11. The decision making process on new vaccines introduction in South Africa.
Ngcobo NJ; Cameron NA
Vaccine; 2012 Sep; 30 Suppl 3():C9-13. PubMed ID: 22939028
[TBL] [Abstract][Full Text] [Related]
12. Decision support in vaccination policies.
Piso B; Wild C
Vaccine; 2009 Oct; 27(43):5923-8. PubMed ID: 19698809
[TBL] [Abstract][Full Text] [Related]
13. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
Girard DZ
Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
[TBL] [Abstract][Full Text] [Related]
14. The need for an evidence-based decision-making process with regard to control of hepatitis A.
Gentile A
J Viral Hepat; 2008 Oct; 15 Suppl 2():16-21. PubMed ID: 18837828
[TBL] [Abstract][Full Text] [Related]
15. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
16. [The precautionary principle: advantages and risks].
Tubiana M
J Chir (Paris); 2001 Apr; 138(2):68-80. PubMed ID: 11319454
[TBL] [Abstract][Full Text] [Related]
17. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
19. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
[TBL] [Abstract][Full Text] [Related]
20. Immunisation in the current management of cystic fibrosis patients.
Malfroot A; Adam G; Ciofu O; Döring G; Knoop C; Lang AB; Van Damme P; Dab I; Bush A;
J Cyst Fibros; 2005 May; 4(2):77-87. PubMed ID: 15978534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
